Biomarin's hemophilia drug meets all endpoints in phase III study

Biomarin has released results from a phase III trial of gene therapy valoctocogene roxaparvovec against severe hemophilia A.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

On Sunday, Biotech company Biomarin publicized results from the largest study of a gene therapy hemophilia A treatment ever, at least according to the company itself.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading